Skip to main content

Table 1 Characteristics of included systematic reviews

From: Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing

Source Type of study Includes AF-studies
N
AF-patients
N
Mean age in years Intervention Comparator mean Follow-Up in years Relevant outcomes
AS IS HS M MB IB GB MI
Adam et al. 2012 [31] MA 3 50,578 >70 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin ≈ 2   X X X     
Agarwal et al. 2012 [27] MA 8 32,053 70–81.5
subgroup ≥75
Warfarin Other thrombophylaxis (Aspirin, Aspirin + clopidogrel, Ximelagatran, Dabigatran, Rivaroxaban, Apixaban, Indraparinux) 1.74a X        
Aguilar et al. 2005 [34] CR + MA 5 2313 69 Warfarin Placebo/control 1.5 X X   X X X   X
Aguilar et al. 2007 [44] MA 8 9598 71 Warfarin, acenocumarol PAI (ASA, ASA + clopidogrel, triflusal) 1.9 X X   X X X   X
Andersen et al. 2008 [37] MA 15 16,058 63.3–81.5 warfarin Placebo, antiplatelets, low dose warfarin, low-dose warfarin + aspirin 1.7      X    
Assiri et al. 2013 [42] MTM 21 80,906 71 Pair-wise comparison of aspirin, aspirin + clopidogrel, warfarin, apixaban, dabigatran, edoxaban, rivaroxaban and placebo 1.85a X    X X X   
Baker et al. 2012 [53] MA 4 44,733 69–73 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin indirect comparison of NOACs 1.8–2.0 X X X X X   X  
Briceno 2015 [29] MA 7 73,978 70–74 NOACs (dabigatran, rivaroxaban, apixaban, edoxaban)
DEVICE (Watchman left atrial occlusion device)
Warfarin 1–2.8 X    X X    
Cameron et al. 2014 [46] MTM 16 82,314 62–83 VKA NOACs
ASA
12 weeks −3.5 years X     X    
Capodanno et al. 2013 [47] MA 3 50,578 71.3 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin 1.9 X X X X X X X X
Chatterje et al. 2013 [63] MA, MTM 6 57,491 69.3–73 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin, ASA 0.23–2.0       X   
Coleman et al. 2012 [35] MA 16 42,983 69.5 Pair-wise comparisons of warfarin (adjusted + low dose), PAI, ximelagatran, dabigatran, placebo/control 2        X  
Cooper et al. 2006 [41] MTM 19 17,833 68.3 Pair-wise comparison of warfarin (adjusted + low dose), ASA, indobufen, ximelagtran, placebo/control 1.8   X    X    
Dogliotti et al. 2013 [48] MA 5 51,895 71.4 NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran) Warfarin 1.75 X X X X X    
Dogliotti et al. 2014 [40] MTM 20 79,808 68.2 Pair-wise comparison of ASA, ASA plus clopidogrel, VKA, dabigatran, rivaroxaban, apixaban or placebo/control >1 X X   X X    
Harenberg et al. 2012 [70] MTM 3 50,578 70–73 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin 1.88   X   X X X   X
Hart et al. 1999 [4] MA 6 9874 70 Adjusted-dose warfarin, PAI Other Antithrombotic regimens placebo
ASA
Mean FU 1.7 y1.7ears, ranged from 1.2 to 2.3 X X   X X X   
Hart et al. 2007 [39] MA 29 28,044 71 Adjusted-dose warfarin, PAI
Placebo/No Treatment
1.5 X X   X X X   
Holster 2013 [33] MA 8 151,578 65–73 NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) Warfarin 12 weeks – 2 years      X   X  
Jia 2014 [54] MA 5 72,961 70–73 NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) Warfarin 1.6–2.8 X X X X X X X X
Lega 2014 [30] MA 3 50,578 70–73 NOACs (apixaban,rivaroxaban, dabigatran) Warfarin 1.8–2 X     X    
Liew et al. 2014 [49] MA 4 71,683 no mean NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) Warfarin 1.8–2.8     X   X   
Lin 2015 [43] MTM 49 897,748 71 Warfarin ASA, dabigatran, rivaroxaban, apixaban, edoxaban, no treatment 12 weeks −3.6 years X X   X X X X  
Lip et al. 2006 [36] MA 13 14,423 68.4 Adjusted-dose warfarin ASA
fixed low-dose warfarin, placebo, ximelagatran
2.13   X   X X    
Miller et al. 2012 [50] MA 3 44,563 71.5 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin 1.91 X X X X X X X X
Providência et al. 2014 [51] MA 7 80,290 71.3 NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran, edoxaban) Warfarin 1.96 X X   X X X X X
Rong 2015 [66] MA 4 71,683 70–73 NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) Warfarin 1.8–2.8      X X X  
Roskell et al. 2010 [67] MTM 26 not stated 71.2 dabigatran Indirect comparison: Placebo, ASA, ASA + clopidgrel, adj. Dose VKA 1.87 X X   X X X   X
Ruff et al. 2014 [87] MA 4 71,683 71.4 NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) Warfarin 2 X X X X X X X X
Sardar et al. 2013 [64] MA 3 50,578 70.6 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin 1.88 X   X X X X X -
Sardar et al. 2014 [32] MA 4 11,562 subgroup for ≥75 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin, ASA 1.1–2.0 X     X    
Schneeweiss et al. 2012 [69] MTM 3 44,535 70–73 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin 1.8–2.0 X     X    
Segal et al. 2000 [38] MA 11 8690 66–80 VKA ASA
ASA + low dose warfarin placebo
0.3–2.6 X    X X    
Senoo 2015 [65] MA 3 1940 70–73 NOAC (rivaroxaban, apixaban, dabigatran) Warfarin 1.3–2.0 X     X X X  
Sharma et al. 2015 [26]
(Subgroup >75 with AF)
MA 5 27,622 >75 Single NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) Warfarin 1.75 X    X     
Taylor et al. 2001 [45]   5 3298 73 Warfarin PAI 2.35 X    X X    X
Testa et al. 2012 [52] MA 3 50,578 71.5 NOACs (dabigatran, apixaban, rivaroxaban) Warfarin >1 X X X X X    X
Verdecchia et al. 2015 [68] MTM 4 71,683 71.5 Indirect comparison (dabigatran, apixaban, rivaroxaban, edoxaban) Dose-adjusted warfarin 2.15 X X   X X X X X
  1. AS All stroke, CR Cochrane Review, GB Gastrointestinal Bleeding, HS Haemorrhagic Stroke, IB Intracranial Bleeding, IS Ischemic stroke, M Mortality, MA Meta-analysis, MB Major Bleeding, MI Myocardial infarction, MA Meta-analysis, NMA network meta-analysis
  2. a Calculated by the review team